Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold Atkins

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Clinical and Experimental Immunology|April 2, 2023
Congenic hematopoietic stem cell transplantation promotes survival of heart allografts in murine models of acute and chronic rejectionHassan Sadozai, Vanessa Rojas-Luengas, Kaveh Farrokhi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 27, 2024
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 3, 2011
Targeting tumor vasculature with an oncolytic virusCaroline J Breitbach, Naomi S De Silva, Theresa J Falls, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 19, 2024
Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic ReviewKednapa Thavorn, Emily Rose Thompson, Srishti Kumar, et al.
Transplantation and Cellular Therapy|January 2, 2026
Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence from Machine Learning and Regression ModelsAshish Narayan Masurekar, Kelly M Burkett, Arya Rahgozar, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 26, 2008
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysisThi Lien-Anh Nguyên, Hesham Abdelbary, Meztli Arguello, et al.
Annals of Neurology|March 7, 2013
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantationPeter J Darlington, Tarik Touil, Jean-Sebastien Doucet, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2015
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaquesLaura Evgin, Sergio A Acuna, Christiano Tanese de Souza, et al.
Nature Communications|March 31, 2015
Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killingRozanne Arulanandam, Cory Batenchuk, Oliver Varette, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR studyDonna E Reece, David H Vesole, Smriti Shrestha, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Clinical and Experimental Immunology|April 2, 2023
Congenic hematopoietic stem cell transplantation promotes survival of heart allografts in murine models of acute and chronic rejectionHassan Sadozai, Vanessa Rojas-Luengas, Kaveh Farrokhi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 27, 2024
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 3, 2011
Targeting tumor vasculature with an oncolytic virusCaroline J Breitbach, Naomi S De Silva, Theresa J Falls, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 19, 2024
Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic ReviewKednapa Thavorn, Emily Rose Thompson, Srishti Kumar, et al.
Transplantation and Cellular Therapy|January 2, 2026
Defining the Limits of Pre-Transplant Risk Prediction in AML: Evidence from Machine Learning and Regression ModelsAshish Narayan Masurekar, Kelly M Burkett, Arya Rahgozar, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 26, 2008
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysisThi Lien-Anh Nguyên, Hesham Abdelbary, Meztli Arguello, et al.
Annals of Neurology|March 7, 2013
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantationPeter J Darlington, Tarik Touil, Jean-Sebastien Doucet, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2015
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaquesLaura Evgin, Sergio A Acuna, Christiano Tanese de Souza, et al.
Nature Communications|March 31, 2015
Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killingRozanne Arulanandam, Cory Batenchuk, Oliver Varette, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR studyDonna E Reece, David H Vesole, Smriti Shrestha, et al.
Pageof 8